Repositorio Dspace

Unnecessary Use of Corticosteroids for managing early mild symptoms of COVID-19 may lead to Rhino-ortibal-cerebral mucormycosis in Patients with Diabetes - a case series from Lahore, Pakistan

Mostrar el registro sencillo del ítem

dc.contributor.author Iqtadar, Somia
dc.contributor.author Hashmat, Masooma
dc.contributor.author Chaudhry, Muhammad-Nabeel-Akbar
dc.contributor.author Mumtaz, Sami-Ullah
dc.contributor.author Abaidullah, Sajid
dc.contributor.author Pascual-Figal, Domingo-A
dc.contributor.author Khan, Amjad
dc.date.accessioned 2025-11-20T07:16:48Z
dc.date.available 2025-11-20T07:16:48Z
dc.date.issued 2022-05
dc.identifier.citation Iqtadar S, Hashmat M, Chaudhry MNA, Mumtaz SU, Abaidullah S, Pascual-Figal DA, et al. Unnecessary Use of Corticosteroids for managing early mild symptoms of COVID-19 may lead to Rhino-ortibal-cerebral mucormycosis in Patients with Diabetes - a case series from Lahore, Pakistan. Therapeutic Advances in Infection. enero de 2022;9:20499361221097417.
dc.identifier.issn 2049-9361
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/21541
dc.description.abstract Rhino-orbital-cerebral mucormycosis (ROCM), a rare but fatal fungal infection, has recently emerged as a serious complication after corticosteroids therapy in COVID-19 patients, predominantly in diabetic and immunocompromised patients. The World Health Organization (WHO) COVID-19 current guidelines recommend corticosteroids administration in hospitalized COVID-19 patients requiring supplementary oxygen or mechanical ventilation. Herein, we report a case series of seven patients with COVID-19; three mild, three moderate, and one severe, from Lahore, Pakistan; all were using corticosteroids for managing their early mild symptoms of COVID-19 at home for around 2-3 weeks without a physician's advise, presented, and admitted with ROCM to Mayo hospital, Lahore, from March to June 2021. Out of the seven patients, five patients had uncontrolled diabetes mellitus (DM) as comorbidity. Eye pain, facial swelling and pain, nasal blockage, and black coloration around eyes, on palate, and oral mucosa were the presenting complaints at the time of admission. All the patients had radiographic imaging, including computed tomography (CT), paranasal sinuses (PNS), or brain magnetic resonance imaging (MRI) carried out at the hospital, which confirmed mucosal thickening and adjacent sinus bony erosions with intracranial extension. All the patients were treated with local debridement of the infected necrotic tissue along with intravenous liposomal Amphotericin B and Posaconazole or Amphotericin B depending on the case. Due to timely management, in six out of seven patients, prognosis was good due to early diagnosis and treatment, while one patient with severe COVID-19 illness deteriorated and died. The misuse of corticosteroids for managing early mild symptoms of COVID-19 in diabetic and other immunocompromised patients can lead to fatal ROCM, which can further increase their risk of developing severe COVID-19 and mortality. It is stressed that only physician's recommended therapeutic advice should be followed for managing early mild symptoms of COVID-19 in self-isolation and avoid the unnecessary use of corticosteroids. This case series also emphasizes that COVID-19 diabetic patients treated with corticosteroids need more vigilant monitoring and high suspicion of early diagnosis and treatment of invasive fungal infection. Early diagnosis and management can reduce morbidity and mortality.
dc.language.iso eng
dc.publisher SAGE PUBLICATIONS LTD
dc.rights http://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.rights.uri Atribución-NoComercial-SinDerivadas 3.0 España *
dc.title Unnecessary Use of Corticosteroids for managing early mild symptoms of COVID-19 may lead to Rhino-ortibal-cerebral mucormycosis in Patients with Diabetes - a case series from Lahore, Pakistan
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 35547833
dc.relation.publisherversion https://journals.sagepub.com/doi/10.1177/20499361221097417
dc.identifier.doi 10.1177/20499361221097417
dc.journal.title Therapeutic Advances in Infectious Disease
dc.identifier.essn 2049-937X


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta